ストックスクリーナーアプリを入手
4.09
3.99%
-0.17
アフターアワーズ：
4.12
0.03
+0.73%
前日終値:
$4.26
開ける：
$4.3
24時間の取引高:
767.82K
Relative Volume:
0.86
時価総額：
$332.91M
収益：
$14.20M
当期純損益:
$-49.59M
株価収益率:
-4.8552
EPS:
-0.8424
ネットキャッシュフロー:
$-35.25M
1週間 パフォーマンス:
-3.99%
1か月 パフォーマンス:
-21.80%
6か月 パフォーマンス:
+102.48%
1年 パフォーマンス:
+300.98%
1日の値動き範囲:
$4.08
$4.34
1週間の範囲:
$4.08
$4.58
52週間の値動き範囲:
$0.9011
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.09 | 346.74M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 開始されました | Oppenheimer | Outperform |
| 2026-01-20 | 開始されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | B. Riley Securities | Buy |
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2025-10-29 | 開始されました | Wedbush | Outperform |
| 2025-10-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-11 | 開始されました | Craig Hallum | Buy |
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Opus Genetics Inc (IRD) 最新ニュース
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - Yahoo Finance
Leerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
IRD Initiates Coverage by Leerink Partners -- Rating 'Outperform' - GuruFocus
Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target - Moomoo
Leerink initiates Opus Genetics stock with outperform rating - Investing.com
Leerink initiates Opus Genetics stock with outperform rating By Investing.com - Investing.com Canada
Foundation Fighting Blindness Retinal Degeneration Fund Sells 1, - GuruFocus
Foundation fighting blindness fund sells $7.4m of Opus Genetics (IRD) stock - Investing.com
Opus Genetics (IRD) investor files exit 13D after stake falls under 5% - Stock Titan
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
Opus Genetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IRD: Gene therapy pipeline advances with pivotal data and regulatory milestones expected in 2024 - TradingView
Lifesci Capital Predicts Lower Earnings for Opus Genetics - MarketBeat
Opus Genetics, Inc. (IRD) reports Q1 loss, misses revenue estimates - MSN
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - MarketBeat
Nantahala Capital (IRD) reports 4.84M shares; 3.16M exercisable within 60 days - Stock Titan
Perceptive (IRD) group holds 9.99% of Opus Genetics; warrants capped by limit - Stock Titan
Caligan Partners reports 8.5% stake in Opus Genetics (IRD) - Stock Titan
HC Wainwright Lifts Earnings Estimates for Opus Genetics - MarketBeat
Balyasny holds 5.11M shares in Opus Genetics (NASDAQ: IRD), includes warrants - Stock Titan
Cantor Fitzgerald Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Opus Genetics (IRD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $11 - Moomoo
IRD Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
Opus Genetics (IRD) Schedule 13G/A: Bios-affiliated funds report 4.53% stake - Stock Titan
Adage Capital (IRD) discloses 8.47% stake in Opus Genetics — 6,029,775 shares - Stock Titan
Chardan Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference - The Manila Times
Citizens cuts Opus Genetics stock price target on share dilution By Investing.com - Investing.com Canada
Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives - Sahm
Is Opus Genetics (IRD) 979.2% Overvalued After Q1 2026? EPS ($0. - GuruFocus
TradingKey - TradingKey
Opus Genetics (IRD) Q1 2026 results show large non-cash loss but stronger cash runway - Stock Titan
Opus Genetics 1Q License & Collaborations Rev Rev $2.2M >IRD - Moomoo
Opus Genetics (IRD) Reports Q1 Revenue Below Expectations - GuruFocus
Opus Genetics 1Q Loss/Shr 75c >IRD - Moomoo
Opus Genetics Reports Q1 2026 Results, Advances Gene Therapy Pipeline for Inherited Retinal Diseases and Secures Funding Through 2029 12 - Minichart
Opus Genetics Releases Q1 2026 Financial Results - AlphaStreet
Opus Genetics earnings missed by $0.62, revenue fell short of estimates - Investing.com Canada
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Opus Genetics (Nasdaq: IRD) posts Q1 2026 loss, extends cash runway into 2029 - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Opus Genetics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
MSN Money - MSN
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics Inc. (IRD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study - markets.businessinsider.com
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):